Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2025; 17(9): 107631
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.107631
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.107631
Postoperative adjuvant management in hepatocellular carcinoma: A review of therapeutic efficacy and prognostic outcomes
Fei Liu, Kai Li, Department of Hepatobiliary Surgery, Lianyungang Clinical College of Nanjing Medical University, The First Affiliated Hospital of Kangda, College of Nanjing Medical University, The First People’s Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang 222061, Jiangsu Province, China
Fei Liu, Jing Zhang, Kai Li, Department of Hepatobiliary Surgery, Jinzhou Medical University Postgraduate Training Base (The First People’s Hospital of Lianyungang), Lianyungang 222061, Jiangsu Province, China
Jing Zhang, Department of Surgery, Chengguan District People’s Hospital of Lanzhou City, Lanzhou 730030, Gansu Province, China
Co-first authors: Fei Liu and Jing Zhang.
Author contributions: Liu F and Zhang J drafted the manuscript, they contributed equally to this article, they are the co-first authors of this manuscript; Zhang J contributed to literature search; Liu F and Li K reviewed and edited the manuscript; and all authors have read and approved the final version to be published.
Supported by the Lianyungang Comprehensive Cancer Management and Technology Advancement Project, No. QN202302; the First People’s Hospital of Lianyungang Young Talent Development Initiative, No. QN2212; and Jiangsu Society of Research Hospital Translational Medicine Research Grant, No. 2024-GDZXKT-01-07.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kai Li, Adjunct Professor, Chief Physician, Department of Hepatobiliary Surgery, Lianyungang Clinical College of Nanjing Medical University, The First Affiliated Hospital of Kangda, College of Nanjing Medical University, The First People’s Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, No. 6 Zhenhua East Road, Lianyungang 222061, Jiangsu Province, China. lkgdwk03178@163.com
Received: April 3, 2025
Revised: May 22, 2025
Accepted: September 9, 2025
Published online: September 27, 2025
Processing time: 176 Days and 2.9 Hours
Revised: May 22, 2025
Accepted: September 9, 2025
Published online: September 27, 2025
Processing time: 176 Days and 2.9 Hours
Core Tip
Core Tip: This article provides a comprehensive evaluation of postoperative adjuvant therapies for hepatocellular carcinoma in patients at high risk of recurrence, detailing the clinical advantages of diverse diagnostic and therapeutic modalities. It highlights the significance and challenges of adjuvant treatment, highlighting the necessity and benefits of multimodal strategies and interdisciplinary collaboration. These insights aim to improve prognosis, extend survival, and inform personalized adjuvant therapy following liver cancer resection.